文献速递类风湿关节炎

巴瑞替尼治疗类风湿关节炎长期安全性:中位4.6年、最长9.3年随访的最终结果

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
PubMed 文献 · Ann Rheum Dis · 2021-10-27

中位随访4.6年、最长9.3年,安全性特征与既往分析相似,未发现新安全信号;恶性肿瘤(除外NMSC)SIR为1.07(95%CI 0.90–1.26),SMR为0.74(95%CI 0.59–0.92)。

要点

  • 严重感染IR为2.6/100患者年,带状疱疹IR为3.0/100患者年,MACE IR为0.5/100患者年。
  • 恶性肿瘤(除外NMSC)SIR 1.07(95%CI 0.90–1.26),死亡SMR 0.74(95%CI 0.59–0.92)。
  • DVT/PE、DVT、PE的IR分别为0.5、0.4、0.3/100患者年,死亡、严重感染、DVT/PE及MACE未见明确剂量差异。

核心结论

  • 在中位4.6年、最长9.3年的长期随访中,巴瑞替尼治疗活动性RA维持与既往分析相似的安全性特征,未发现新的安全信号。

主要发现

  • 全巴瑞替尼人群严重感染、带状疱疹、MACE的IR分别为2.6、3.0、0.5/100患者年。
  • ≥50岁且≥1个心血管危险因素患者中,MACE的IR为0.77(95%CI 0.56–1.04)。
  • 恶性肿瘤(除外NMSC)前48周IR为0.6,此后稳定(IR 1.0);SIR为1.07(95%CI 0.90–1.26),SMR为0.74(95%CI 0.59–0.92)。
  • DVT/PE、DVT、PE的IR分别为0.5(95%CI 0.38–0.61)、0.4(95%CI 0.26–0.45)、0.3(95%CI 0.18–0.35)/100患者年。
  • 死亡、严重感染、DVT/PE及MACE的暴露校正IR未见明确剂量差异。

临床怎么用

  • 长期使用巴瑞替尼治疗活动性RA时,可参考上述长期安全性数据,关注严重感染、带状疱疹、MACE、恶性肿瘤及静脉血栓栓塞事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report long-term safety from the completed extension trial of baricitinib, an oral selective Janus kinase inhibitor, in patients with active rheumatoid arthritis (RA). METHODS: Treatment-emergent adverse events are summarised from an integrated database (9 phase III/II/Ib and 1 long-term extension) of patients who received any baricitinib dose (All-bari-RA). Standardised incidence ratio (SIR) for malignancy (excluding non-melanoma skin cancer (NMSC)) and standardised mortality ratio (SMR) were estimated. Additional analysis was done in a subset of patients who had ever taken 2 mg or 4 mg baricitinib. RESULTS: 3770 patients received baricitinib (14 744 patient-years of exposure (PYE)). All-bari-RA incidence rates (IRs) per 100 patient-years at risk were 2.6, 3.0 and 0.5 for serious infections, herpes zoster and major adverse cardiovascular events (MACE), respectively. In patients aged ≥50 with ≥1 cardiovascular risk factor, the IR for MACE was 0.77 (95% CI 0.56 to 1.04). The IR for malignancy (excluding NMSC) during the first 48 weeks was 0.6 and remained stable thereafter (IR 1.0). The SIR for malignancies excluding NMSC was 1.07 (95% CI 0.90 to 1.26) and the SMR was 0.74 (95% CI 0.59 to 0.92). All-bari-RA IRs for deep vein thrombosis (DVT)/pulmonary embolism (PE), DVT and PE were 0.5 (95% CI 0.38 to 0.61), 0.4 (95% CI 0.26 to 0.45) and 0.3 (95% CI 0.18 to 0.35), respectively. No clear dose differences were noted for exposure-adjusted IRs (per 100 PYE) for deaths, serious infections, DVT/PE and MACE. CONCLUSIONS: In this integrated analysis including long-term data of baricitinib from 3770 patients (median 4.6 years, up to 9.3 years) with active RA, baricitinib maintained a similar safety profile to earlier analyses. No new safety signals were identified. TRIAL REGISTRATION NUMBER: NCT01185353, NCT00902486, NCT01469013, NCT01710358, NCT02265705, NCT01721044, NCT01721057, NCT01711359 and NCT01885078.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Taylor PC, Takeuchi T, Burmester GR, et al. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2021. PMID: 34706874. doi:10.1136/annrheumdis-2021-221276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。